Study Finds Cross-Border Pediatric Trial Participation Feasible With Language Support
Research published in Pediatric Research in February 2026 demonstrates that pediatric patients can successfully participate in cross-border clinical trials when language barriers are addressed through translation services and multilingual communication strategies.
A study published in February 2026 in Pediatric Research demonstrates that pediatric patients can successfully participate in cross-border clinical trials when language barriers are addressed through appropriate translation services and multilingual communication strategies. The research, analyzing data from SJD Barcelona Children's Hospital, provides evidence that international patient inclusion is feasible and should prioritize potential medical benefits rather than using language or home country as eligibility criteria.
The study analyzed retrospective data from 2011 to 2024 of clinical trials incorporating international patients at SJD Barcelona Children's Hospital. One hundred eighty-one patients from both European and non-European countries (N = 44) were screened, with 37.02% of patients from Europe and 62.98% from non-European countries. Twenty-one clinical studies were included in the analysis.
In 52.38% of the studies, translation services were provided by the site, while in 14.28% they were provided by the sponsor. In 33.33% of the studies, no translation was necessary because site staff could communicate with families in Spanish or English. The research found that 57.14% of the studies included one or more patient-reported outcome measures or quality of life scales, requiring in some cases the use of validated translations in the mother tongue of the patient.
The research underscores the imperative for harmonization of regulatory frameworks and ethical standards between countries to streamline patient recruitment and protect vulnerable pediatric populations. Regulatory inconsistencies may cause delays or exclusions, thereby potentially compromising trial diversity and scientific robustness.
Quantitative analysis based on cross-sectional data from multiple ongoing trials demonstrates that multilingual approaches significantly reduce dropout rates among pediatric patients, indirectly improving the statistical power and generalizability of research findings. The study provides compelling evidence that increased language inclusivity correlates with enhanced recruitment rates and greater participant retention.
Cross-border access to clinical trials in Europe lacks specific regulation, despite the existence of Directive 2011/24/EU on cross-border healthcare and the application of patients' rights. Regulation (EU) No 536/2014 of the European Parliament ensures harmonization of rules for conducting clinical trials across the European Union but has no reference to the concept of cross-border clinical trials or multi-region studies in which patients from different Member States participate in a clinical trial executed in a different Member State where they reside.
Language diversity in Europe, with 24 official languages, is a key factor that must be considered when including international pediatric patients in multi-country studies. Language barriers can affect not only the comprehension of trial protocols but also broader aspects of patient experience, such as trust-building and adherence to treatment regimens.
The study identifies best practices in deploying language services, highlighting technologies such as real-time translation software, multilingual e-consent platforms, and culturally tailored educational materials. These innovations address the ethical mandate to ensure fully informed consent, especially for minors whose understanding depends heavily on their caregivers' comprehension.
The research emphasizes that language inclusion must go beyond mere translation, focusing on the age-appropriate conveyance of trial information. This tailored approach is vital for respecting the autonomy of pediatric participants while aligning with international ethical guidelines, such as those promulgated by the Declaration of Helsinki and the International Conference on Harmonisation.
Cross-border cooperation faces operational challenges, including data sharing protocols, privacy concerns, and the logistical orchestration of multinational trial sites. Misaligned data protection laws and infrastructural disparities can hinder smooth conduct of pediatric clinical trials. Enhancing interoperability of electronic health records and adopting unified trial management systems emerge as crucial strategies to mitigate these barriers.
The SJD Barcelona Children's Hospital Clinical Trials Unit operates under a one-stop-shop model, managing clinical studies with a special focus on rare diseases and centralizing all the needs of international patients, including translations, accommodation, and visas. The inclusion of international patients in pediatric clinical studies is particularly critical for pediatric rare disease clinical trials for conditions with no approved treatment, where only a few countries participate.
The study notes that the final decision regarding the inclusion of international patients lies with the sponsor. Flexibility in including international patients directly impacts the study plan and execution, preventing time deviations. The authors recommend a multidisciplinary approach involving linguists, ethicists, pediatric specialists, and patient advocates to co-develop patient-centered materials.
The research frames clinical trial participation as both a scientific and a social justice issue, noting that language and border-related exclusions can exacerbate health disparities. The study calls on stakeholders—including regulators, sponsors, and healthcare providers—to prioritize inclusive strategies that dismantle linguistic and geographic barriers.